Looks like you’re on the UK site. Choose another location to see content specific to your location
GlaxoSmithKline expands Rockville site to support Benlysta production
GlaxoSmithKline has announced plans to spend $139 million (107.47 million pounds) to expand its biopharmaceutical manufacturing site in Rockville, Maryland.
The investment will be used to provide additional internal capacity to increase bulk drug substance production by nearly 50 percent, in response to increased demand for the lupus therapy Benlysta.
GlaxoSmithKline's Rockville site is also expected to house production of a new subcutaneous form of the drug, which is currently under review for approval by US and European health authorities.
Benlysta is indicated for adult patients with active, autoantibody-positive systemic lupus erythematosus who are receiving standard therapy. Since 2014, the product has grown at least 18 percent annually in the US on a constant exchange rate basis.
Sheri Mullen, vice-president for immunology and rare diseases at GlaxoSmithKline, said: "We are so pleased that on the first day of Lupus Awareness Month, we are able to announce this expansion in Rockville, increasing our ability to provide this important medicine to patients."
The manufacturing site consists of two facilities for large and small-scale manufacturing, employing more than 400 scientists, engineers and manufacturing and quality professionals.
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips
and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard